Overall verdict
Neutral
4.8/10
1-year performance
-30.72%
Score breakdown
Down 30.7% over 1 year, 10% of the 52-week range.
Strongest: Growth 9.4/10. Weakest: Shareholder return 0.0/10.
6 analysts, target +1.7% vs the price.
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names.
The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases ;
and FYB208 and FYB209 that is indicated for immunology areas. Formycon AG has cooperation agreements with Biocelys S.A. and Santo Biosimilar GmbH in connection with a biosimilar candidate. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Sector
Health Care
Industry
Biotechnology
Primary listing
Xetr
Germany
CEO
Dr. Stefan Glombitza
Founded
1999
Employees
203
Revenue / employee
219 094 EUR
Next earnings
March 25, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
26.95 EUR
52-week low
13.60 EUR
1-year performance
-30.72%
Declining
Year-to-date performance
-42.08%
Declining
Drawdown
-44.34%
Major drawdown
Position in the 52-week range
10% of range
Against the world ETF
Over 16 years, from December 2010 to October 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 4.0 times harder.
10 000 € placed at the end of December 2010 are worth today
| Formycon | 19 466 € |
| World ETF | 60 693 € |
| STOXX Europe 600 | 36 717 € |
| Risk-free placement | 11 226 € |
The risk
- Shaking:the share moves 4.0 times as much as the world ETF.
- Worst fall:-82 % between January 2023 and March 2026. 10 000 € placed at the top fell to 1 818 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Formycon earned less than the world ETF since 2010
Value of 10 000 € placed at the end of December 2010, dividends reinvested, in euros
- Formycon: 19 466 €
- World ETF: 60 693 €
- STOXX Europe 600: 36 717 €
- Risk-free placement: 11 226 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 9.85 EUR - 11.11 EUR (comparables only)
Gross margin 22.8%, the company loses 41.0% of its revenue, ROIC -6.2%, ROE -6.3%.
Net margin
-41.04%
Negative
Sector -208.32%|S&P 13.40%
Gross margin
22.81%
Low
Return on equity (ROE)
-6.33%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-6.21%
Negative
Free cash flow margin (FCF)
-9.18%
Negative
Margin stability
82.6 pts
Very uneven
Revenue to net income
Growth
9.4/10Revenue up 242.5% over 1 year, 5.4% a year over 5.
Revenue (trailing 12 months)
59.5M EUR
Revenue growth (1y)
242.50%
Hyper-growth
Revenue growth (3y)
4.66%
Moderate
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.7/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E
—
N/A (loss)
EV / EBITDA
22.3x
Expensive
Sector 13.2x|S&P 15.5x
PEG
—
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
10.48 EUR
Deeply overvalued
Market cap
264M EUR
Financial strength
7.5/10Cash covers 608.1% of the debt, net debt/EBITDA -4.6x.
Net debt / EBITDA
-4.6x
Net cash
Gearing (net debt / equity)
-11.22%
Net cash
Cash
50.4M EUR
Cash / market cap
19.05%
Very solid
Cash / total debt
608.08%
Net cash
Interest coverage
-2.3x
Stretched
Net debt
-42.1M EUR
Equity
375M EUR
Closed daily candles, 2 years
Last close on November 11, 2026: 14.96 EUR
- MM2017.98
- MM5019.03
- MM20019.50
- RSI 1430.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.27%
200-day average slope, 3 months
-6.63%
50-day average slope, 1 month
-1.99%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
5.58 % per day
Volatility change
+86.66%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.67 (6) | -0.62 (2) | 73 (6) | -5 (5) | -12 (6) |
| 2027 | 1.24 (6) | 1.11 (3) | 112 (6) | 51 (5) | 22 (6) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of November 3, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 293M USD | Not meaningful (loss) | -41.0 % | 242.5 % | -6.2 % | -4.6x | -2.1 % | -30.7 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
